Samantha M Harrison1, Melissa Y Wei2, Lois E Lamerato3, Joshua G Petrie4, Emily Toth Martin5. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109-2029, USA. Electronic address: samharri@umich.edu. 2. Division of General Medicine, Michigan Medicine, 2800 Plymouth Rd Bldg 16, Ann Arbor, MI 48109-2800, USA. Electronic address: weimy@med.umich.edu. 3. Henry Ford Health System, One Ford Place, 5C, Detroit, MI 48202 USA. Electronic address: LLAMERA1@hfhs.org. 4. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109-2029, USA. Electronic address: jpetrie@umich.edu. 5. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109-2029, USA. Electronic address: etmartin@umich.edu.
Abstract
OBJECTIVE: Patients with chronic conditions have higher rates of severe influenza-related illness and mortality. However, influenza vaccination coverage in high-risk populations continues to be suboptimal. We describe the association between cumulative disease morbidity, measured by a previously validated multimorbidity index, and influenza vaccination among community-dwelling adults. METHODS: We obtained interview and medical record data for participants ≥18 years who sought outpatient care for influenza-like illness between 2011 and 2016 as part of an outpatient-based study of influenza vaccine effectiveness. We defined cumulative disease morbidity by using medical diagnosis codes to calculate a multimorbidity-weighted index (MWI) for each participant. MWI and influenza vaccination status was evaluated by logistic regression. Akaike information criterion was calculated for all models. RESULTS: Overall, 1458 (48%) of participants out of a total of 3033 received influenza vaccination. The median MWI was 0.9 (IQR 0.00-3.5) and was higher among vaccinated participants (median 1.6 versus 0.0; p < 0.001). We found a positive linear association between MWI and vaccination, and vaccination percentages were compared between categories of MWI. Compared to patients with no multimorbidity (MWI = 0), odds of vaccination were 17% higher in the second category (MWI 0.01-1.50; [OR: 1.17, 95% CI: 0.92-1.50]), 58% higher in the third category (MWI 1.51-3.00; [OR: 1.58, 95% CI: 1.26-1.99]), 130% higher in the fourth category (MWI 3.01-6.00; [OR: 2.30, 95% CI: 1.78-2.98]) and 214% higher in the fifth category (MWI 6.01-45.00;[OR: 3.14, 95% CI: 2.41-4.10]). Participants defined as high-risk had 86% greater odds of being vaccinated than non-high-risk individuals (OR: 1.86, 95% CI: 1.56-2.21). The AIC was lowest for MWI compared with high-risk conditions. CONCLUSIONS: Our results suggest a dose response relationship between level of multimorbidity and likelihood of influenza vaccination. Compared with high-risk condition designations, MWI provided improved precision and a better model fit for the measurement of chronic disease and influenza vaccination.
OBJECTIVE:Patients with chronic conditions have higher rates of severe influenza-related illness and mortality. However, influenza vaccination coverage in high-risk populations continues to be suboptimal. We describe the association between cumulative disease morbidity, measured by a previously validated multimorbidity index, and influenza vaccination among community-dwelling adults. METHODS: We obtained interview and medical record data for participants ≥18 years who sought outpatient care for influenza-like illness between 2011 and 2016 as part of an outpatient-based study of influenza vaccine effectiveness. We defined cumulative disease morbidity by using medical diagnosis codes to calculate a multimorbidity-weighted index (MWI) for each participant. MWI and influenza vaccination status was evaluated by logistic regression. Akaike information criterion was calculated for all models. RESULTS: Overall, 1458 (48%) of participants out of a total of 3033 received influenza vaccination. The median MWI was 0.9 (IQR 0.00-3.5) and was higher among vaccinated participants (median 1.6 versus 0.0; p < 0.001). We found a positive linear association between MWI and vaccination, and vaccination percentages were compared between categories of MWI. Compared to patients with no multimorbidity (MWI = 0), odds of vaccination were 17% higher in the second category (MWI 0.01-1.50; [OR: 1.17, 95% CI: 0.92-1.50]), 58% higher in the third category (MWI 1.51-3.00; [OR: 1.58, 95% CI: 1.26-1.99]), 130% higher in the fourth category (MWI 3.01-6.00; [OR: 2.30, 95% CI: 1.78-2.98]) and 214% higher in the fifth category (MWI 6.01-45.00;[OR: 3.14, 95% CI: 2.41-4.10]). Participants defined as high-risk had 86% greater odds of being vaccinated than non-high-risk individuals (OR: 1.86, 95% CI: 1.56-2.21). The AIC was lowest for MWI compared with high-risk conditions. CONCLUSIONS: Our results suggest a dose response relationship between level of multimorbidity and likelihood of influenza vaccination. Compared with high-risk condition designations, MWI provided improved precision and a better model fit for the measurement of chronic disease and influenza vaccination.
Authors: Jean Yves Le Reste; Patrice Nabbe; Benedicte Manceau; Charilaos Lygidakis; Christa Doerr; Heidrun Lingner; Slawomir Czachowski; Miguel Munoz; Stella Argyriadou; Ana Claveria; Bernard Le Floch; Marie Barais; Peter Bower; Harm Van Marwijk; Paul Van Royen; Claire Lietard Journal: J Am Med Dir Assoc Date: 2013-02-12 Impact factor: 4.669
Authors: Peng-jun Lu; Tammy A Santibanez; Walter W Williams; Jun Zhang; Helen Ding; Leah Bryan; Alissa O'Halloran; Stacie M Greby; Carolyn B Bridges; Samuel B Graitcer; Erin D Kennedy; Megan C Lindley; Indu B Ahluwalia; Katherine LaVail; Laura J Pabst; LaTreace Harris; Tara Vogt; Machell Town; James A Singleton Journal: MMWR Surveill Summ Date: 2013-10-25
Authors: Christian Brettschneider; Hanna Leicht; Horst Bickel; Anne Dahlhaus; Angela Fuchs; Jochen Gensichen; Wolfgang Maier; Steffi Riedel-Heller; Ingmar Schäfer; Gerhard Schön; Siegfried Weyerer; Birgitt Wiese; Hendrik van den Bussche; Martin Scherer; Hans-Helmut König Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery Journal: Clin Infect Dis Date: 2016-10-04 Impact factor: 20.999
Authors: Brendan Flannery; Richard K Zimmerman; Larisa V Gubareva; Rebecca J Garten; Jessie R Chung; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Suzanne E Ohmit; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Pedro A Piedra; Vasiliy P Mishin; Anton P Chesnokov; Sarah Spencer; Swathi N Thaker; John R Barnes; Angie Foust; Wendy Sessions; Xiyan Xu; Jacqueline Katz; Alicia M Fry Journal: J Infect Dis Date: 2016-05-06 Impact factor: 7.759
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Sonja J Olsen; Joseph S Bresee; Karen R Broder; Ruth A Karron Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-07 Impact factor: 17.586
Authors: Maria A Ukhanova; Carrie J Tillotson; Miguel Marino; Nathalie Huguet; Ana R Quiñones; Brigit A Hatch; Teresa Schmidt; Jennifer E DeVoe Journal: Am J Prev Med Date: 2020-09-22 Impact factor: 5.043
Authors: Michael J Wu; Jessie R Chung; Sara S Kim; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Michael Reis; Madhava Beeram; Emily T Martin; Arnold S Monto; Mary Patricia Nowalk; Richard Zimmerman; Tammy A Santibanez; James A Singleton; Manish Patel; Brendan Flannery Journal: Vaccine Date: 2021-02-15 Impact factor: 4.169
Authors: Constantina Boikos; Mahrukh Imran; Van Hung Nguyen; Thierry Ducruet; Gregg C Sylvester; James A Mansi Journal: Open Forum Infect Dis Date: 2021-04-02 Impact factor: 3.835